Cell therapy company Chimeric Therapeutics (ASX:CHM) has completed the manufacturing and quality release for CHM 2101 viral vector.
The company says this is a key milestone in advancing CHM 2101 towards the clinic.
CHM 2101 is a first-in-class, third-generation autologous CAR-T cell therapy invented at the University of Pennsylvania.
Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer, with the data demonstrating strong evidence of efficacy with complete eradication of eight different types of gastrointestinal cancers with no relapse or toxicity.
Chimeric says it is currently focused on advancing CHM 2101 towards a phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.
“Vector supply continues to significantly challenge the cell therapy industry with current backlogs of more than a year to access vector manufacturing,” said Chimeric CEO and managing director Jennifer Chow. “Securing vector supply for the CHM 2101 Phase 1A clinical trial marks a significant milestone for advancing CHM 2101 towards the clinic and patients that need novel therapies to treat advanced gastrointestinal and neuroendocrine tumours.”
